Last reviewed · How we verify
IN10018
At a glance
| Generic name | IN10018 |
|---|---|
| Also known as | BI 853520, BI853520 |
| Sponsor | InxMed (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- IN10018 Combination Therapy in Previously-treated Solid Tumors (PHASE1, PHASE2)
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
- A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (PHASE3)
- IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
- IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (PHASE1)
- IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial (PHASE2)
- A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation (PHASE1)
- IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IN10018 CI brief — competitive landscape report
- IN10018 updates RSS · CI watch RSS
- InxMed (Shanghai) Co., Ltd. portfolio CI